Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real‐world study
ObjectivesFecal microbiota transplantation (FMT) has been recommended for the treatment of recurrent Clostridioides difficile infection (CDI). We aimed to evaluate the therapeutic efficacy and safety of washed microbiota transplantation (WMT), a new method of FMT, for CDI across various medical sett...
Gespeichert in:
| Veröffentlicht in: | Journal of digestive diseases 2023-10, Vol.24 (10), p.540-549 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 549 |
|---|---|
| container_issue | 10 |
| container_start_page | 540 |
| container_title | Journal of digestive diseases |
| container_volume | 24 |
| creator | Wu, Xia Ai, Ru Jun Xu, Jie Wen, Quan Pan, Hua Qin Zhang, Zhi Hua Ning, Wang Fang, Ying Ding, Da Fa Wang, Quan Han, Shuang Liu, Xiao Wu, Mei Jia, Zhen Yu Jia, Song Lin, Tao Cui, Bo Ta Nie, Yong Zhan Wang, Xin Zhang, Fa Ming |
| description | ObjectivesFecal microbiota transplantation (FMT) has been recommended for the treatment of recurrent Clostridioides difficile infection (CDI). We aimed to evaluate the therapeutic efficacy and safety of washed microbiota transplantation (WMT), a new method of FMT, for CDI across various medical settings.MethodsThis multicenter real‐world cohort study included CDI patients undergoing WMT. The primary outcome was the clinical cure rate of CDI within 8 weeks after WMT. Secondary outcomes included the CDI recurrence rate and reduction in total abdominal symptom score (TASS) during the follow‐up period. Adverse events related to WMT were recorded.ResultsAltogether 90.7% (49/54) of CDI patients achieved clinical cure after treated with WMT. The cure rate was 83.3% for cases with severe and complicated CDI (ScCDI) (n = 30) and 100% for non‐ScCDI cases (n = 24) (P = 0.059). No difference was observed in the clinical cure rate between patients with first and recurrent CDI (91.9% vs 88.2%, P = 0.645). One week post‐WMT, TASS showed a remarkable decrease compared to that at baseline (P |
| doi_str_mv | 10.1111/1751-2980.13227 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2863301890</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2891870693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-cca505c86c1f7153ef2414508c1b4e6eb31765183a4ccb72f3e117e0c0692eac3</originalsourceid><addsrcrecordid>eNpdkT1PwzAQhi0EEqUws1piYQm14yRO2aqKL6kSC4jRcpyzcOXExXaEuvET-I38EpwWdeCW-9Bzr3TvIXRJyQ1NMaO8pFk-r1PL8pwfoclhcnyoeX6KzkJYE1JWvK4mKLzJ8A4t7ozyrjEuShy97MPGyj7KaFyPtfN4aV2I3rTGmRYCbo3WRhkL2PQa1Ijd4gXudwvS4m6w0SjoI3jsQdqfr-9P522LQxza7Tk60dIGuPjLU_R6f_eyfMxWzw9Py8UqU6xgMVNKlqRUdaWo5rRkoPOCFiWpFW0KqKBhlFclrZkslGp4rhlQyoEoUs1zkIpN0fVed-PdxwAhis4EBTadBm4IIq8rxgit5yShV__QtRt8OmWk5rTmSZMlaranklcheNBi400n_VZQIsYniNFmMVoudk9gvxdufDI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2891870693</pqid></control><display><type>article</type><title>Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real‐world study</title><source>Wiley Online Library All Journals</source><creator>Wu, Xia ; Ai, Ru Jun ; Xu, Jie ; Wen, Quan ; Pan, Hua Qin ; Zhang, Zhi Hua ; Ning, Wang ; Fang, Ying ; Ding, Da Fa ; Wang, Quan ; Han, Shuang ; Liu, Xiao ; Wu, Mei ; Jia, Zhen Yu ; Jia, Song ; Lin, Tao ; Cui, Bo Ta ; Nie, Yong Zhan ; Wang, Xin ; Zhang, Fa Ming</creator><creatorcontrib>Wu, Xia ; Ai, Ru Jun ; Xu, Jie ; Wen, Quan ; Pan, Hua Qin ; Zhang, Zhi Hua ; Ning, Wang ; Fang, Ying ; Ding, Da Fa ; Wang, Quan ; Han, Shuang ; Liu, Xiao ; Wu, Mei ; Jia, Zhen Yu ; Jia, Song ; Lin, Tao ; Cui, Bo Ta ; Nie, Yong Zhan ; Wang, Xin ; Zhang, Fa Ming</creatorcontrib><description>ObjectivesFecal microbiota transplantation (FMT) has been recommended for the treatment of recurrent Clostridioides difficile infection (CDI). We aimed to evaluate the therapeutic efficacy and safety of washed microbiota transplantation (WMT), a new method of FMT, for CDI across various medical settings.MethodsThis multicenter real‐world cohort study included CDI patients undergoing WMT. The primary outcome was the clinical cure rate of CDI within 8 weeks after WMT. Secondary outcomes included the CDI recurrence rate and reduction in total abdominal symptom score (TASS) during the follow‐up period. Adverse events related to WMT were recorded.ResultsAltogether 90.7% (49/54) of CDI patients achieved clinical cure after treated with WMT. The cure rate was 83.3% for cases with severe and complicated CDI (ScCDI) (n = 30) and 100% for non‐ScCDI cases (n = 24) (P = 0.059). No difference was observed in the clinical cure rate between patients with first and recurrent CDI (91.9% vs 88.2%, P = 0.645). One week post‐WMT, TASS showed a remarkable decrease compared to that at baseline (P < 0.001). Totally, 8.2% (4/49) of patients suffered CDI recurrence during the follow‐up period. A WHO performance score of 4, age ≥65 years, higher TASS score, and higher Charlson comorbidity index score were potential risk factors for efficacy (P = 0.018, 0.03, 0.01, 0.034, respectively). Four (3.8%) transient adverse events related to WMT were observed.ConclusionsThis study emphasizes the attractive value of WMT for CDI. Early WMT may be recommended for CDI, especially for those in serious condition or with complex comorbidities.Trial registrationClinicalTrials.gov, no. NCT03895593 (registered on 27 March 2019).</description><identifier>ISSN: 1751-2972</identifier><identifier>EISSN: 1751-2980</identifier><identifier>DOI: 10.1111/1751-2980.13227</identifier><language>eng</language><publisher>Richmond: Wiley Subscription Services, Inc</publisher><subject>Adverse events ; Clostridioides difficile ; Comorbidity ; Fecal microflora ; Microbiota ; Patients ; Recurrent infection ; Risk factors ; Transplantation</subject><ispartof>Journal of digestive diseases, 2023-10, Vol.24 (10), p.540-549</ispartof><rights>2023 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-cca505c86c1f7153ef2414508c1b4e6eb31765183a4ccb72f3e117e0c0692eac3</citedby><cites>FETCH-LOGICAL-c343t-cca505c86c1f7153ef2414508c1b4e6eb31765183a4ccb72f3e117e0c0692eac3</cites><orcidid>0000-0003-4157-1144 ; 0000-0002-6335-301X ; 0000-0002-2636-1053</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Wu, Xia</creatorcontrib><creatorcontrib>Ai, Ru Jun</creatorcontrib><creatorcontrib>Xu, Jie</creatorcontrib><creatorcontrib>Wen, Quan</creatorcontrib><creatorcontrib>Pan, Hua Qin</creatorcontrib><creatorcontrib>Zhang, Zhi Hua</creatorcontrib><creatorcontrib>Ning, Wang</creatorcontrib><creatorcontrib>Fang, Ying</creatorcontrib><creatorcontrib>Ding, Da Fa</creatorcontrib><creatorcontrib>Wang, Quan</creatorcontrib><creatorcontrib>Han, Shuang</creatorcontrib><creatorcontrib>Liu, Xiao</creatorcontrib><creatorcontrib>Wu, Mei</creatorcontrib><creatorcontrib>Jia, Zhen Yu</creatorcontrib><creatorcontrib>Jia, Song</creatorcontrib><creatorcontrib>Lin, Tao</creatorcontrib><creatorcontrib>Cui, Bo Ta</creatorcontrib><creatorcontrib>Nie, Yong Zhan</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Zhang, Fa Ming</creatorcontrib><title>Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real‐world study</title><title>Journal of digestive diseases</title><description>ObjectivesFecal microbiota transplantation (FMT) has been recommended for the treatment of recurrent Clostridioides difficile infection (CDI). We aimed to evaluate the therapeutic efficacy and safety of washed microbiota transplantation (WMT), a new method of FMT, for CDI across various medical settings.MethodsThis multicenter real‐world cohort study included CDI patients undergoing WMT. The primary outcome was the clinical cure rate of CDI within 8 weeks after WMT. Secondary outcomes included the CDI recurrence rate and reduction in total abdominal symptom score (TASS) during the follow‐up period. Adverse events related to WMT were recorded.ResultsAltogether 90.7% (49/54) of CDI patients achieved clinical cure after treated with WMT. The cure rate was 83.3% for cases with severe and complicated CDI (ScCDI) (n = 30) and 100% for non‐ScCDI cases (n = 24) (P = 0.059). No difference was observed in the clinical cure rate between patients with first and recurrent CDI (91.9% vs 88.2%, P = 0.645). One week post‐WMT, TASS showed a remarkable decrease compared to that at baseline (P < 0.001). Totally, 8.2% (4/49) of patients suffered CDI recurrence during the follow‐up period. A WHO performance score of 4, age ≥65 years, higher TASS score, and higher Charlson comorbidity index score were potential risk factors for efficacy (P = 0.018, 0.03, 0.01, 0.034, respectively). Four (3.8%) transient adverse events related to WMT were observed.ConclusionsThis study emphasizes the attractive value of WMT for CDI. Early WMT may be recommended for CDI, especially for those in serious condition or with complex comorbidities.Trial registrationClinicalTrials.gov, no. NCT03895593 (registered on 27 March 2019).</description><subject>Adverse events</subject><subject>Clostridioides difficile</subject><subject>Comorbidity</subject><subject>Fecal microflora</subject><subject>Microbiota</subject><subject>Patients</subject><subject>Recurrent infection</subject><subject>Risk factors</subject><subject>Transplantation</subject><issn>1751-2972</issn><issn>1751-2980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdkT1PwzAQhi0EEqUws1piYQm14yRO2aqKL6kSC4jRcpyzcOXExXaEuvET-I38EpwWdeCW-9Bzr3TvIXRJyQ1NMaO8pFk-r1PL8pwfoclhcnyoeX6KzkJYE1JWvK4mKLzJ8A4t7ozyrjEuShy97MPGyj7KaFyPtfN4aV2I3rTGmRYCbo3WRhkL2PQa1Ijd4gXudwvS4m6w0SjoI3jsQdqfr-9P522LQxza7Tk60dIGuPjLU_R6f_eyfMxWzw9Py8UqU6xgMVNKlqRUdaWo5rRkoPOCFiWpFW0KqKBhlFclrZkslGp4rhlQyoEoUs1zkIpN0fVed-PdxwAhis4EBTadBm4IIq8rxgit5yShV__QtRt8OmWk5rTmSZMlaranklcheNBi400n_VZQIsYniNFmMVoudk9gvxdufDI</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Wu, Xia</creator><creator>Ai, Ru Jun</creator><creator>Xu, Jie</creator><creator>Wen, Quan</creator><creator>Pan, Hua Qin</creator><creator>Zhang, Zhi Hua</creator><creator>Ning, Wang</creator><creator>Fang, Ying</creator><creator>Ding, Da Fa</creator><creator>Wang, Quan</creator><creator>Han, Shuang</creator><creator>Liu, Xiao</creator><creator>Wu, Mei</creator><creator>Jia, Zhen Yu</creator><creator>Jia, Song</creator><creator>Lin, Tao</creator><creator>Cui, Bo Ta</creator><creator>Nie, Yong Zhan</creator><creator>Wang, Xin</creator><creator>Zhang, Fa Ming</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4157-1144</orcidid><orcidid>https://orcid.org/0000-0002-6335-301X</orcidid><orcidid>https://orcid.org/0000-0002-2636-1053</orcidid></search><sort><creationdate>20231001</creationdate><title>Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real‐world study</title><author>Wu, Xia ; Ai, Ru Jun ; Xu, Jie ; Wen, Quan ; Pan, Hua Qin ; Zhang, Zhi Hua ; Ning, Wang ; Fang, Ying ; Ding, Da Fa ; Wang, Quan ; Han, Shuang ; Liu, Xiao ; Wu, Mei ; Jia, Zhen Yu ; Jia, Song ; Lin, Tao ; Cui, Bo Ta ; Nie, Yong Zhan ; Wang, Xin ; Zhang, Fa Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-cca505c86c1f7153ef2414508c1b4e6eb31765183a4ccb72f3e117e0c0692eac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse events</topic><topic>Clostridioides difficile</topic><topic>Comorbidity</topic><topic>Fecal microflora</topic><topic>Microbiota</topic><topic>Patients</topic><topic>Recurrent infection</topic><topic>Risk factors</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Xia</creatorcontrib><creatorcontrib>Ai, Ru Jun</creatorcontrib><creatorcontrib>Xu, Jie</creatorcontrib><creatorcontrib>Wen, Quan</creatorcontrib><creatorcontrib>Pan, Hua Qin</creatorcontrib><creatorcontrib>Zhang, Zhi Hua</creatorcontrib><creatorcontrib>Ning, Wang</creatorcontrib><creatorcontrib>Fang, Ying</creatorcontrib><creatorcontrib>Ding, Da Fa</creatorcontrib><creatorcontrib>Wang, Quan</creatorcontrib><creatorcontrib>Han, Shuang</creatorcontrib><creatorcontrib>Liu, Xiao</creatorcontrib><creatorcontrib>Wu, Mei</creatorcontrib><creatorcontrib>Jia, Zhen Yu</creatorcontrib><creatorcontrib>Jia, Song</creatorcontrib><creatorcontrib>Lin, Tao</creatorcontrib><creatorcontrib>Cui, Bo Ta</creatorcontrib><creatorcontrib>Nie, Yong Zhan</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Zhang, Fa Ming</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of digestive diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Xia</au><au>Ai, Ru Jun</au><au>Xu, Jie</au><au>Wen, Quan</au><au>Pan, Hua Qin</au><au>Zhang, Zhi Hua</au><au>Ning, Wang</au><au>Fang, Ying</au><au>Ding, Da Fa</au><au>Wang, Quan</au><au>Han, Shuang</au><au>Liu, Xiao</au><au>Wu, Mei</au><au>Jia, Zhen Yu</au><au>Jia, Song</au><au>Lin, Tao</au><au>Cui, Bo Ta</au><au>Nie, Yong Zhan</au><au>Wang, Xin</au><au>Zhang, Fa Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real‐world study</atitle><jtitle>Journal of digestive diseases</jtitle><date>2023-10-01</date><risdate>2023</risdate><volume>24</volume><issue>10</issue><spage>540</spage><epage>549</epage><pages>540-549</pages><issn>1751-2972</issn><eissn>1751-2980</eissn><abstract>ObjectivesFecal microbiota transplantation (FMT) has been recommended for the treatment of recurrent Clostridioides difficile infection (CDI). We aimed to evaluate the therapeutic efficacy and safety of washed microbiota transplantation (WMT), a new method of FMT, for CDI across various medical settings.MethodsThis multicenter real‐world cohort study included CDI patients undergoing WMT. The primary outcome was the clinical cure rate of CDI within 8 weeks after WMT. Secondary outcomes included the CDI recurrence rate and reduction in total abdominal symptom score (TASS) during the follow‐up period. Adverse events related to WMT were recorded.ResultsAltogether 90.7% (49/54) of CDI patients achieved clinical cure after treated with WMT. The cure rate was 83.3% for cases with severe and complicated CDI (ScCDI) (n = 30) and 100% for non‐ScCDI cases (n = 24) (P = 0.059). No difference was observed in the clinical cure rate between patients with first and recurrent CDI (91.9% vs 88.2%, P = 0.645). One week post‐WMT, TASS showed a remarkable decrease compared to that at baseline (P < 0.001). Totally, 8.2% (4/49) of patients suffered CDI recurrence during the follow‐up period. A WHO performance score of 4, age ≥65 years, higher TASS score, and higher Charlson comorbidity index score were potential risk factors for efficacy (P = 0.018, 0.03, 0.01, 0.034, respectively). Four (3.8%) transient adverse events related to WMT were observed.ConclusionsThis study emphasizes the attractive value of WMT for CDI. Early WMT may be recommended for CDI, especially for those in serious condition or with complex comorbidities.Trial registrationClinicalTrials.gov, no. NCT03895593 (registered on 27 March 2019).</abstract><cop>Richmond</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/1751-2980.13227</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-4157-1144</orcidid><orcidid>https://orcid.org/0000-0002-6335-301X</orcidid><orcidid>https://orcid.org/0000-0002-2636-1053</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1751-2972 |
| ispartof | Journal of digestive diseases, 2023-10, Vol.24 (10), p.540-549 |
| issn | 1751-2972 1751-2980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2863301890 |
| source | Wiley Online Library All Journals |
| subjects | Adverse events Clostridioides difficile Comorbidity Fecal microflora Microbiota Patients Recurrent infection Risk factors Transplantation |
| title | Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real‐world study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A58%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Washed%20microbiota%20transplantation%20for%20Clostridioides%20difficile%20infection:%20A%20national%20multicenter%20real%E2%80%90world%20study&rft.jtitle=Journal%20of%20digestive%20diseases&rft.au=Wu,%20Xia&rft.date=2023-10-01&rft.volume=24&rft.issue=10&rft.spage=540&rft.epage=549&rft.pages=540-549&rft.issn=1751-2972&rft.eissn=1751-2980&rft_id=info:doi/10.1111/1751-2980.13227&rft_dat=%3Cproquest_cross%3E2891870693%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2891870693&rft_id=info:pmid/&rfr_iscdi=true |